Image

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.

Non Recruiting
18-75 years
All
Phase N/A

Powered by AI

Overview

TUMOSPEC is a national family study designed to measure the relative and absolute risk of cancer for carriers of deleterious mutations to these "new" breast cancer (BC) susceptibility genes. Index cases will be enrolled consecutively from patients attending an appointment at one of the Unicancer centres, with no other inclusion criteria, and offered a BRCA1/2 analysis as part of their care plan. A panel of 24 TUMOSPEC genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study. If a mutation is found, the index cases will be asked to invite their first and second degree family members and their cousins to take part in the study, regardless of whether they have cancer. Saliva samples will be then taken and used for a targeted analysis of the familial abnormality. Each participant will also complete an epidemiological questionnaire in order to gather information about his/her medical history and any exposure to various risk factors. All medical and genotype data will be centralised at the Genetic Epidemiology Research Platform (PIGE, INSERM). The cumulative mutation frequency for all genes is estimated at 10%. Penetrance will be analysed using methods designed to minimise selection bias. The expression spectrum of the mutations will also be described. For genes where the number of mutated families is too low, the data may be contributed to international consortia. The main project will be preceded by a two-year feasibility study, using the same inclusion criteria and logistic circuits. It is this pilot study to which the current funding application relates.

Eligibility

Inclusion criteria:

Index case eligibility:

        Any person with an indication for a BRCA1/BRCA2 gene analysis and who has been offered
        TUMOSPEC panel screening.
        Age ≥18 years.
        Family member eligibility:
        Family members will be eligible if the mutation identified in the Index Case is considered
        deleterious.
        Any family member to the first and second decree or a cousin of the Index Case. Family
        members from both sides of the family will be invited to take part.
        Age ≥18 years.
        Exclusion Criteria:
        People deprived of their civil liberties or who are under judicial protection or
        guardianship.
        Patients unable to answer the questionnaire for social or psychological reasons.
        Children of the index cases, of any age.

Study details
    Hereditary Breast and Ovarian Cancer
    Mutation

NCT03246841

UNICANCER

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.